Citigroup Inc Autolus Therapeutics PLC Transaction History

Citigroup Inc

$196 Billion
Q2 2025

A detailed history of Citigroup Inc transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Citigroup Inc holds 3,822 shares of AUTL stock, worth $4,892. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,822

Previous 3,163 20.83%

Holding current value

$4,892

Previous $4,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	BUY	$1.14 - $2.4 $751 - $1,581	659 Added 20.83%	3,822 $8,000
Q1 2025 May 12, 2025	SELL	$1.55 - $2.68 $258 - $447	-167 Reduced 5.02%	3,163 $4,000
Q4 2024 Feb 12, 2025	SELL	$2.18 - $4.8 $466 - $1,027	-214 Reduced 6.04%	3,330 $7,000
Q3 2024 Nov 12, 2024	SELL	$3.38 - $4.69 $45,319 - $62,883	-13,408 Reduced 79.09%	3,544 $12,000
Q2 2024 Aug 12, 2024	SELL	$3.33 - $5.68 $218,557 - $372,795	-65,633 Reduced 79.47%	16,952 $58,000
Q1 2024 May 10, 2024	BUY	$5.39 - $7.29 $431,415 - $583,491	80,040 Added 3144.99%	82,585 $526,000
Q4 2023 Feb 09, 2024	BUY	$2.13 - $6.63 $5,420 - $16,873	2,545 New	2,545 $16,000
Q4 2022 Feb 09, 2023	SELL	$1.74 - $3.27 $1,158 - $2,177	-666 Reduced 87.86%	92 $0
Q3 2022 Nov 10, 2022	SELL	$2.04 - $3.76 $405 - $748	-199 Reduced 20.79%	758 $2,000
Q2 2022 Aug 10, 2022	SELL	$2.04 - $4.68 $569 - $1,305	-279 Reduced 22.57%	957 $3,000
Q1 2022 May 12, 2022	SELL	$3.52 - $5.46 $1,791 - $2,779	-509 Reduced 29.17%	1,236 $5,000
Q4 2021 Feb 10, 2022	SELL	$5.1 - $7.0 $7,415 - $10,178	-1,454 Reduced 45.45%	1,745 $9,000
Q3 2021 Nov 10, 2021	BUY	$5.32 - $7.37 $17,018 - $23,576	3,199 New	3,199 $21,000

Others Institutions Holding AUTL

# of Institutions

100

Shares Held

164M

Call Options Held

Put Options Held

39.3K

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $116M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account